Tim Maughan

University of Liverpool — United Kingdom

Medicine · Health Sciences

61h-index19.9kcitations634works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(263), Gastric Cancer Management and Outcomes(129), Genetic factors in colorectal cancer(125), Colorectal Cancer Surgical Treatments(115), Colorectal and Anal Carcinomas(100)

Publications627 total

BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2026
Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
2025Open Access
AI-powered immune profiling from histopathology slides for chemo-radiotherapy outcome prediction in rectal cancer: a study using clinical trial and real-world cohorts
EBioMedicine·2025· 1 citedOpen Access
729MO Circulating tumour (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER
Annals of Oncology·2025
Abstract P11: TEX264 DRIVES SELECTIVE AUTOPHAGY OF DNA LESIONS TO PROMOTE DNA REPAIR AND CELL SURVIVAL
Cancer Research·2025Open Access
The colorectal liver metastasis growth pattern phenotype is not dependent on genotype
British Journal of Cancer·2025Open Access
Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial
Radiotherapy and Oncology·2025· 3 citedOpen Access
Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis
JCO oncology advances.·2025Open Access
Analysis of <scp> <i>IDH1</i> </scp> and <scp> <i>IDH2</i> </scp> mutations as causes of the hypermethylator phenotype in colorectal cancer
The Journal of Pathology·2025· 2 citedOpen Access
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
Journal of Clinical Oncology·2025· 4 cited
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i> -Mutated Colorectal Cancer
New England Journal of Medicine·2025· 63 citedOpen Access
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
Future Oncology·2025Open Access
1913 Tumour-to-stroma ratio identified by artificial intelligence impacts cancer outcomes in a phase III randomised rectal chemo-radiotherapy trial
Radiotherapy and Oncology·2025
1994 Clinical outcomes from EMERALD trial: A phase I evaluating ultra-hypofractionated MR-Guided Adaptive SABR (SMART) for localized pancreatic cancer.
Radiotherapy and Oncology·2025
2109 Real-world clinical outcomes of stereotactic MR-guided adaptive radiotherapy (SMART) for localized pancreatic cancer: A retrospective cohort analysis
Radiotherapy and Oncology·2025
page 1 of 32Next →

Frequent Co-authors

Richard Kaplan(15), Michel Seymour(13), Jeremy P. Cheadle(11), Richard Adams(10), Stephen Falk(10), David J. Fisher(9), Ian Tomlinson(9), Susan M. Farrington(8), Rachel Kerr(8), Claire Palles(8), Angela Meade(7), Shelley Idziaszczyk(7), Philip Quirke(7), Susan D. Richman(7), Simon J. Leedham(7), Mark A. Jenkins(7), Christopher G. Smith(6), John Bridgewater(6), Richard S. Houlston(6), Enric Domingo(6)